Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

Fig. 3

Direct average monthly costs by patient cohort and line of treatment. Costs in cohort A 1st line (HT) were significantly lower compared with costs in cohort A 2nd line (chemotherapy) and cohort C (any therapy; p < 0.001 for both comparisons, Mann-Whitney U test). Abbreviation: HT, hormone therapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us